Gastrointestinal Cancer

Hagen F. Kennecke, MD, discusses treatment selection, peptide receptor radionuclide therapy, and remaining challenges in the field of gastroenteropancreatic neuroendocrine tumors.

Heinz-Josef Lenz, MD, FACP, discusses the next steps for the trial examining the onvansertib combination and sheds light on the possibility of this regimen eventually being used in the frontline setting.

Diane M. Simeone, MD, discusses the benefit of using a gemcitabine “sandwich approach” in patients with resectable pancreatic cancer.

The FDA has granted an orphan drug designation to MIV-818 for the treatment of patients with hepatocellular carcinoma.

Michael J. Overman, MD, professor in the Department of Gastrointestinal Medical Oncology of the Division of Cancer Medicine and committee vice chair at The University of Texas MD Anderson Cancer Center, discusses ongoing research with immunotherapy in microsatellite stable (MSS) colorectal cancer (CRC).

Andrea Wang-Gillam, MD, PhD, discusses potential next steps with a novel combination regimen in pancreatic ductal adenocarcinoma.

Aman Chauhan, MD, discusses recent developments and emerging therapies in gastroenteropancreatic neuroendocrine tumors.

Manuel Hidalgo Medina, MD, PhD, discusses some of the research he presented at the 2020 ACCR Virtual Annual Meeting and future areas of exciting efforts being made in pancreatic cancer.

FGFR2 fusions are significantly less common in endemic fluke-associated cholangiocarcinoma compared with non–fluke-associated cholangiocarcinoma, demonstrating that distinct etiologies could affect the molecular landscape of cholangiocarcinoma tumors.

The combination of nivolumab and regorafenib demonstrated promising antitumor activity in patients with gastric and colorectal cancer.

During an OncLive® scientific interchange, panelists discussed the current treatment landscape for patients with gastroenteropancreatic-neuroendocrine tumors and the need for improved novel therapies.

Tanios S. Bekaii-Saab, MD, FACP, medical oncologist, medical director, Cancer Clinical Research Office, vice chair and section chief, Medical Oncology, Department of Internal Medicine, Mayo Clinic, discusses moving metastatic treatment strategies to the adjuvant setting in colorectal cancer (CRC).

Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.

A European panel has recommended approval of encorafenib in combination with cetuximab for the treatment of adult patients with BRAF V600E–mutant metastatic colorectal cancer.

Hirva Mamdani, MD, discusses the need to develop novel therapies in locally advanced esophageal and gastroesophageal junction adenocarcinoma.

Andrea Wang-Gillam, MD, PhD, discusses the results of a phase 1 study with defactinib in patients with pancreatic ductal adenocarcinoma.

Vincent J. Picozzi Jr, MD, discusses the prognostic value of pathologic response to neoadjuvant chemotherapy in patients with resected pancreatic cancer.

Ryan W. Huey, MD, assistant professor, Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the landscape of hepatocellular carcinoma (HCC).

Vincent Chung, MD, discusses findings from a pilot study evaluating the safety of adding dietary supplements to chemotherapy in patients with unresectable pancreatic cancer.

Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.

The use of circulating tumor DNA via baseline tumor tissue or rebiopsy led to the identification of several MET mutations previously unidentified upon progression on savolitinib in patients with gastric cancer, as well as MET amplifications as drivers of resistance to the agent during monotherapy treatment of those with MET-amplified disease.

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Ryan W. Huey, MD, highlights the evolving treatment options in the hepatocellular carcinoma paradigm and discusses challenges and next steps in the field.

The FDA has approved pemigatinib for the treatment of patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, as detected by an FDA-approved test.

The FDA has granted Fast Track Designations to surufatinib for the treatment of advanced and progressive pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors in patients who are not amenable for surgery.